Anti-PD-1 antibodies, however, have become the gold standard treatment for melanoma based on studies comparing anti-PD-1 to anti-CTLA-4 and to chemotherapy (Topalian et al., 2012). This evidence concerns the gene CTLA4 and melanoma.